Critical reviews in oncology/hematology
-
Crit. Rev. Oncol. Hematol. · May 2019
Meta AnalysisRisk of fatal adverse events in cancer patients treated with sunitinib.
Sunitinib, a tyrosine kinase inhibitor, is widely used in several malignancies. However, the association between sunitinib administration and fatal adverse events (FAEs) is not completely clear. Here, to calculate the overall incidence and relative risks (RRs) of FAE induced by sunitinib, PubMed and Embase were searched from inception to September 2017 for phase III randomized controlled trials (RCTs). ⋯ The association between sunitinib and FAEs varied significantly with treatment duration or treatment strategy, but not with tumor types or sunitinib dosage. The most common causes of FAEs was hemorrhage (26.9%). In conclusion, the use of sunitinib was associated with an increased risk of FAEs in patients with solid tumors.